Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period

Abstract

In Stargardt disease, autofluorescence imaging may serve as a monitoring tool and definitely decreased autofluorescence and total area as outcome measures for interventional clinical trials that aim to slow disease progression. Rates of progression depended mainly on initial lesion size.